SCHEMBL3288155

SCHEMBL3288155

CCN(CC)C(=O)C1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
KDM4E B2RXH2 4/20 0.42
PKM P14618 1/20 0.42
POLB P06746 1/20 0.41
BCHE P06276 1/20 0.40
LMNA P02545 2/20 0.39
KMT2A Q03164 2/20 0.37
PIK3CD O00329 1/20 0.37
MAPT P10636 1/20 0.37
MAPK1 P28482 1/20 0.37
MEN1 O00255 1/20 0.36
USP2 O75604 1/20 0.36
HTT P42858 2/20 0.36
HPGD P15428 1/20 0.36
CYP3A4 P08684 1/20 0.35
TSHR P16473 1/20 0.35
CYP2C19 P33261 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12086280 0.88 BCHE (0.38) ALDH1A1KDM4EPKMPOLBBCHE
SCHEMBL19674600 0.84 PIK3CD (0.41) ALDH1A1KDM4EPKMPOLBBCHE
SCHEMBL15074482 0.84 PIK3CD (0.41) ALDH1A1KDM4EPKMPOLBBCHE
SCHEMBL1289738 0.84 ALDH1A1 (0.47) ALDH1A1KDM4EPKMBCHELMNA
Hydrochloric Acid SCHEMBL1289689 0.82 ALDH1A1 (0.46) ALDH1A1KDM4EPKMBCHELMNA
SCHEMBL5988184 0.82 BCHE (0.41) ALDH1A1PKMPOLBBCHEKMT2A
SCHEMBL1053598 0.80 BCHE (0.50) ALDH1A1KDM4EPKMBCHEMAPT
SCHEMBL13058298 0.80 BCHE (0.50) ALDH1A1KDM4EPKMBCHEMAPT
SCHEMBL3628742 0.78 BCHE (0.49) ALDH1A1KDM4EPKMBCHEMAPT
SCHEMBL21362892 0.78 BCHE (0.49) ALDH1A1KDM4EPKMBCHEMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8304423-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICAL INCORPORATED (US) 2012-11-06 US disclosed
US-20120196857-A9 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-02 US disclosed
US-20120004226-A1 Modulators of Muscarinic Receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-01-05 US disclosed
US-8003660-B2 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-08-23 US disclosed
US-20080306287-A1 Process for Preparing Tetrahydropyran-4-Carboxylic Acid Compound UBE INDUSTRIES, LTD. (JP) 2008-12-11 US disclosed
CN-101061102-A Process for producing tetrahydropyran-4-carboxylic acid compound UBE INDUSTRIES (JP) 2007-10-24 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080306287-A1 Process for Preparing Tetrahydropyran-4-Carboxylic Acid Compound ADH1A, ADH1C, HPD ALDH1A1 29/4885KDM4E 621/4885PKM 910/4885
US-20120004226-A1 Modulators of Muscarinic Receptors CHRM3, CHRM5, CHRM2 ALDH1A1 2356/4885KDM4E 3396/4885PKM 2294/4885
US-20120196857-A9 Modulators of Muscarinic Receptors CHRM3, CHRM5, CHRM2 ALDH1A1 2356/4885KDM4E 3396/4885PKM 2294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.